Cell & Gene therapy

In this episode Lucy Chard is joined by Rajiv Khatau to discuss the importance of looking into new therapeutic areas and some of the more niche areas of pharmaceuticals, and investing in the future of the industry. 

Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. 

In the last week, the US FDA has granted approval/accelerated approval to three different oncology drugs, each from different drugmakers with different indications. 

A new genome study undertaken in the US, accounting for a diverse range of people, has led to the discovery of nearly 300 million new genetic variants, which could inform markers of disease. 

To conclude the ‘Partnering for Success’ track at CPHI Barcelona 2023 (October 24–26th) we held a panel, with a range of experts, on the CDMO outlook. 

Innovative biotech company Biotheus has signed a deal with BioNTech to manufacture, market, and distribute their latest anti-tumour therapy around the world. 

In our packed out content sessions at CPHI Barcelona this year, we focus on some of the hottest topics coming up in the pharma industry, with each track sponsored by a leading expert in the field. 

Joining the strong number of cancer therapies being approved in 2023 is the CAR-T cell therapy from Invectys, the clinical-stage immuno-oncology company.

Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. 

In collaboration with Thermo Fisher Scientific, UCSF has opened a new manufacturing site aimed at accelerating advanced cell and gene therapies for cancer, rare diseases, and other illnesses.

A USD $42 million collaboration between AbbVie and Anima Biotech aims to leverage the latter’s mRNA Lightning technology platform to enhance therapeutic development programs in oncology and immunology.

A multi-year collaboration between BioNTech and the Government of the United Kingdom will see the expansion of the company’s presence in the UK, focusing on areas like cancer immunotherapies and infectious disease vaccines.

Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio.